Share

June 2015; 2 (3) Clinical/Scientific NotesOpen Access

Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody–positive encephalitis

James P. Orengo, Melike Pekmezci, Bruce A.C. Cree
First published April 9, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000101
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
634

Share

Article Information

vol. 2 no. 3 e101
DOI: 
https://doi.org/10.1212/NXI.0000000000000101
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 21, 2014
  • Accepted in final form March 9, 2015
  • First Published April 9, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. James P. Orengo, MD, PhD,
    2. Melike Pekmezci, MD and
    3. Bruce A.C. Cree, MD, PhD, MAS
  1. James P. Orengo, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Melike Pekmezci, MD and
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Spouse- from Stryker Corp, (2) Spouse-form NuVasive Inc

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) UCSF Department of Pathology

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Bruce A.C. Cree, MD, PhD, MAS
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Annals of Neurology, editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Abbvie, Biogen Idec, EMD Serono, Genzyme, MedImmune, Novartis, Sanofi Aventis, Teva Neurosciences

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Contracted research support (including clinical trials) from Acorda, Avanir, Biogen Idec, EMD Serono, Hoffman La Roche, MedImmune, Novartis and Teva Neurosciences.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Biogen Idec- expert consultant

  1. From the Departments of Neurology (J.P.O., B.A.C.C.) and Pathology (M.P.), University of California, San Francisco.
  1. Correspondence to Dr. Cree: bruce.cree{at}ucsf.edu
View Full Text

Article usage

Article usage: May 2015 to December 2022

AbstractFullPdfSource
Apr 2015811810Highwire
Apr 201502813pmc
May 2015462317Highwire
May 201504412pmc
Jun 201514426542Highwire
Jun 20150286pmc
Jul 2015462410Highwire
Jul 20150117pmc
Aug 201564214Highwire
Aug 20150186pmc
Sep 20151355Highwire
Sep 20150195pmc
Oct 20159167Highwire
Oct 20150142pmc
Nov 2015874Highwire
Nov 20150418pmc
Dec 2015742Highwire
Dec 20150297pmc
Jan 201617110Highwire
Jan 20160196pmc
Feb 2016782Highwire
Feb 20160124pmc
Mar 20162775Highwire
Mar 2016062pmc
Apr 2016372Highwire
Apr 20160144pmc
May 20161071Highwire
May 2016082pmc
Jun 20161275Highwire
Jun 20160132pmc
Jul 20161861Highwire
Jul 20160125pmc
Aug 20161641Highwire
Aug 20160153pmc
Sep 2016741Highwire
Sep 2016092pmc
Oct 20161853Highwire
Oct 20160132pmc
Nov 2016914Highwire
Nov 20160132pmc
Dec 2016582Highwire
Dec 2016063pmc
Jan 2017732Highwire
Jan 2017040pmc
Feb 2017520Highwire
Feb 2017052pmc
Mar 2017921Highwire
Mar 20170151pmc
Apr 2017612Highwire
Apr 2017178pmc
May 2017353Highwire
May 2017277pmc
Jun 2017622Highwire
Jun 2017188pmc
Jul 2017110Highwire
Jul 20171910pmc
Aug 2017442Highwire
Aug 2017299pmc
Sep 2017240Highwire
Sep 2017168pmc
Oct 2017611Highwire
Oct 201721010pmc
Nov 2017620Highwire
Nov 20171810pmc
Dec 2017160Highwire
Jan 2018053Highwire
Feb 2018082Highwire
Mar 20181133Highwire
Apr 20180123Highwire
Apr 20181911pmc
May 20180322Highwire
Jun 20180212Highwire
Jun 2018156pmc
Jul 20180324Highwire
Aug 20181263Highwire
Aug 2018289pmc
Sep 2018061Highwire
Oct 20181214Highwire
Nov 20180230Highwire
Dec 20181351Highwire
Jan 20190160Highwire
Feb 20190163Highwire
Mar 2019193Highwire
Apr 20191257Highwire
May 2019254Highwire
Jun 20196146Highwire
Jul 2019186Highwire
Aug 2019155Highwire
Sep 2019273Highwire
Oct 20191155Highwire
Nov 2019054Highwire
Dec 20193142Highwire
Jan 2020182Highwire
Feb 2020041Highwire
Mar 2020015Highwire
Apr 2020061Highwire
May 2020092Highwire
Jun 2020055Highwire
Jul 20200100Highwire
Aug 2020074Highwire
Sep 20201145Highwire
Oct 2020175Highwire
Nov 20201411Highwire
Dec 2020168Highwire
Jan 20211205Highwire
Feb 2021253Highwire
Mar 2021044Highwire
Apr 2021069Highwire
May 20212103Highwire
Jun 20210171Highwire
Jul 202111114Highwire
Aug 20211249Highwire
Sep 2021084Highwire
Oct 202111419Highwire
Nov 20210714Highwire
Dec 20210186Highwire
Jan 2022032Highwire
Feb 20220104Highwire
Mar 20220167Highwire
Apr 20221106Highwire
May 20221149Highwire
Jun 2022096Highwire
Jul 2022050Highwire
Aug 20221201Highwire
Sep 202212211Highwire
Oct 20221197Highwire
Nov 202225315Highwire
Dec 20220207Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me